NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

Dova Pharmaceuticals Inc (NASDAQ:DOVA) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The firm earned $3.52 million during the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. View Dova Pharmaceuticals' Earnings History.

6 equities research analysts have issued 1-year price objectives for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they expect Dova Pharmaceuticals' stock price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

News articles about DOVA stock have trended very positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a daily sentiment score of 3.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Dova Pharmaceuticals.

Some companies that are related to Dova Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Allakos (ALLK), Axsome Therapeutics (AXSM), Agios Pharmaceuticals (AGIO), Genmab A/S (GMAB), Apellis Pharmaceuticals (APLS), Deciphera Pharmaceuticals (DCPH), Taro Pharmaceutical Industries (TARO), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Insmed (INSM), Alkermes (ALKS), Uniqure (QURE), Arena Pharmaceuticals (ARNA) and Biohaven Pharmaceutical (BHVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), TESARO (TSRO), TherapeuticsMD (TXMD), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Immunomedics (IMMU).

(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DOVA stock can currently be purchased for approximately $28.04.

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

The official website for Dova Pharmaceuticals is http://www.dova.com/.

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]